Additionally, they found that lower miR-22 and higher GLUT1 expression levels are correlated with short disease-free survival times and poor overall survival in patients with BC, which indicates that miR-22 and GLUT1 expression could be a valuable indicator of BC progression and prognosis [154]. The gene discussed is SLC2A1; the disease is breast cancer.